Diligence memo · auto-generated · as of July 2, 2026
Enjamb Labs
Enjamb Labs: limited disclosed financing to assess.
Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.
Businessfiled
Enjamb Labs operates in Pharma, based in San Francisco, CA, USA. Where drug teams run their entire program, discovery to FDA approval
Sub-sector tags: B2B, ai/ml, pharma.
Capital & rounds (filed)filed
Enjamb Labs has raised — in disclosed capital across 0 recorded rounds, aggregated from public filings.
Valuation (modeled)modeled
No modeled valuation — too little disclosed financing to estimate one.
Financing rhythm & timingmixed
Not enough dated financing history to read a financing rhythm.
Comparablesmixed
Capital scale ranks ahead of 16% of Pharma peers (310 compared).
Modeled value ranks above 16% of those peers.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.